Xolair For Peanut Allergy
This article was originally published in The Pink Sheet Daily
Genentech, Novartis and Tanox expect to begin patient enrollment for a Phase II proof-of-concept study of Xolair to treat peanut allergy "early this year.
You may also be interested in...
A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability
Pfizer's success will depend on its ability to negotiate the paradox of increasing demand for pharmaceuticals coupled with growing attempts to restrain costs, CEO Jeffrey Kindler said
Pfizer will continue to support the insomnia product for up to six months.